Enrique Arredondo

Mr. Enrique Arredondo

Texas A&M Health Science Center-College of Pharmacy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2021 in Cureus
Verified
Journal Article
Open access
EAEnrique Arredondo
Enrique Arredondo
GUGeorge Udeani
George Udeani
MHMichael Horseman
Michael Horseman
THTrager D. Hintze
Trager D. Hintze
Salim SuraniSalim Surani
Salim Surani
The cost of health care has been rising in the United States and globally and will continue to increase. Intensive care unit (ICU) care carries a significant portion of the cost for the hospitals. The Institute of Medicine and subsequent studies have suggested that medication errors account for significant morbidity, mortality, and cost, frequently encountered in the ICU. Over the past three decades, clinical pharmacists have emerged from dispensing medication to getting involved in direct patient care and have become an integral part of the multidisciplinary critical care team. Clinical pharmacists play a significant role in reducing medication errors and costs, medication reconciliation, antibiotic stewardship, and patient and health care provider education. This review will discuss the health care and ICU cost, the evolving role of clinical pharmacists in managing critically ill patients, and their contributions in the ICU to mitigate the risks, improve patient outcomes, and decrease health care costs.

2 February 2022 in Medicina
Verified
Journal Article
Open access
PDF file
EAEnrique Arredondo
Enrique Arredondo
MDMonica DeLeon
Monica DeLeon
IMIshimwe Masozera
Ishimwe Masozera
LPLadan Panahi
Ladan Panahi
GUGeorge Udeani
George Udeani
TSTori L. Shiver
Tori L. Shiver
Obstructive sleep apnea (OSA) remains a prominent disease state characterized by the recurrent collapse of the upper airway while sleeping. To date, current treatment may include continuous positive airway pressure (CPAP), lifestyle changes, behavioral modification, mandibular advancement devices, and surgical treatment. However, due to the desire for a more convenient mode of management, pharmacological treatment has been thoroughly investigated as a means for a potential alternative in OSA treatment. OSA can be distinguished into various endotypic or phenotypic classes, allowing pharmacological treatment to better target the root cause or symptoms of OSA. Some medications available for use include antidepressants, CNS stimulants, nasal decongestants, carbonic anhydrase inhibitors, and potassium channel blockers. This review will cover the findings of currently available and future study medications that could potentially play a role in OSA therapy.

21 April 2021 in Hospital Practice
Verified
Journal Article
Closed access
EAEnrique Arredondo
Enrique Arredondo
Rahul KashyapRahul Kashyap
Rahul Kashyap
Salim SuraniSalim Surani
Salim Surani
The COVID-19 pandemic caused the United States to hit record numbers of COVID-19 cases: peak unemployment of 14.7%, an increase in $4 trillion in national debt, and an estimated 3.4% GDP decline. The current socio-economic environment the pandemic created is just an earthquake that can create a tsunami that is bound to hit the healthcare system and can be felt around the globe. This tsunami is composed of a post-pandemic increase in healthcare facilities admission of indigent patients, decrease in medical reimbursement, and high operating costs to maintain healthcare workers, which can cause a synergistic effect that can lead to healthcare facilities experiencing significant negative total revenue. Time is of the essence, and it is imperative to make a collective effort from all healthcare professionals and legislatures to shift the nation’s attention to the issue at hand that can threaten the closure of many healthcare facilities post-pandemic.